NCT05001282

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Terminated Phase 1, PHASE2 Last updated 7 August 2024

What this trial tests

Phase 1, PHASE2 trial testing ELU001 in Ovarian Cancer in 79 participants. Terminated before completion.

Timeline

13 September 2021

Primary endpoint
7 June 2024

7 June 2024

Quick facts

Lead sponsor	Elucida Oncology
Phase	Phase 1, PHASE2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	79
Start date	13 September 2021
Primary completion	7 June 2024
Estimated completion	7 June 2024
Sites	18 locations across United States

Drugs / interventions tested

• ELU001 — full drug profile →

Conditions studied

• Ovarian Cancer — all drugs for Ovarian Cancer →
• Ovarian Neoplasms — all drugs for Ovarian Neoplasms →
• Ovarian Carcinoma — all drugs for Ovarian Carcinoma →
• Endometrial Cancer — all drugs for Endometrial Cancer →

Sponsor

Elucida Oncology — full company profile →

Who can join

18 and older, any sex, with Ovarian Cancer or Ovarian Neoplasms. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study, ELU- FRα-1, was focused on adult subjects who have advanced, recurrent or refractory folate receptor alpha (FRα) overexpressing tumors considered to be topoisomerase 1 inhibitor-sensitive based on scientific literature, and, in the opinion of the Investigator, have no other meaningful life-prolonging therapy options available.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Antibody-drug conjugates in lung cancer: dawn of a new era?
   Coleman N, Yap TA, Heymach JV, Meric-Bernstam F, et al · · 2023 · cited 89× · PMID 36631624 · DOI 10.1038/s41698-022-00338-9
2. Cancer nanomedicine: a review of nano-therapeutics and challenges ahead.
   Nirmala MJ, Kizhuveetil U, Johnson A, G B, et al · · 2023 · cited 86× · PMID 36926304 · DOI 10.1039/d2ra07863e
3. Colorectal Cancer: Disease Process, Current Treatment Options, and Future Perspectives.
   Adebayo AS, Agbaje K, Adesina SK, Olajubutu O. · · 2023 · cited 65× · PMID 38004598 · DOI 10.3390/pharmaceutics15112620
4. Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities.
   Sorolla MA, Hidalgo I, Sorolla A, Montal R, et al · · 2021 · cited 42× · PMID 34680186 · DOI 10.3390/cancers13205037
5. Targeted Nanocarrier-Based Drug Delivery Strategies for Improving the Therapeutic Efficacy of PARP Inhibitors against Ovarian Cancer.
   Gralewska P, Gajek A, Marczak A, Rogalska A. · · 2024 · cited 21× · PMID 39125873 · DOI 10.3390/ijms25158304
6. Nanomedicine-Based Drug-Targeting in Breast Cancer: Pharmacokinetics, Clinical Progress, and Challenges.
   Rahman M, Afzal O, Ullah SNMN, Alshahrani MY, et al · · 2023 · cited 18× · PMID 38162753 · DOI 10.1021/acsomega.3c07345
7. Emerging Applications of Nanoparticles in the Diagnosis and Treatment of Breast Cancer.
   Oehler JB, Rajapaksha W, Albrecht H. · · 2024 · cited 16× · PMID 39063977 · DOI 10.3390/jpm14070723
8. Ovarian clear cell carcinoma: open questions on the management and treatment algorithm.
   Rosso R, Turinetto M, Borella F, Chopin N, et al · · 2025 · cited 10× · PMID 39846983 · DOI 10.1093/oncolo/oyae325